CM
ZVRA icon

Caption Management’s Zevra Therapeutics ZVRA Stock Holding History

Caption Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.38M Sell
255,236
-284,876
-53% -$2.57M 0.01% 777
2025
Q4 		$4.84M Buy
540,112
+30,021
+6% +$284K 0.03% 532
2025
Q3 		$4.85M Buy
+510,091
New +$5.12M 0.04% 503
2025
Q2 		– Sell
-16,997
Closed -$138K – 1986
2025
Q1 		$127K Buy
+16,997
New +$135K ﹤0.01% 1330
2024
Q4 		– Sell
-62,000
Closed -$430K – 1886
2024
Q3 		$430K Buy
+62,000
New +$421K 0.01% 950
2022
Q4 		– Sell
-10,000
Closed -$62K – 1792
2022
Q3 		$62K Buy
+10,000
New +$56.6K ﹤0.01% 1373
2022
Q2 		– Sell
-7,500
Closed -$34.2K – 1908
2022
Q1 		$37K Sell
7,500
-12,639
-63% -$80.4K ﹤0.01% 1376
2021
Q4 		$176K Buy
+20,139
New +$180K ﹤0.01% 1428

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Caption Management's ZVRA Position: Q1 2026 in Review

Caption Management reduced its Zevra Therapeutics (ZVRA) stake by 53% in Q1 2026, selling an estimated $2.57M and leaving 255,236 shares worth $2.38M. The position accounts for 0.01% of the portfolio, ranked #777.

Caption Management first reported a position in ZVRA in Q4 2021 and has held it in 8 quarters since. The position peaked at $4.85M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Caption Management held 255,236 shares of Zevra Therapeutics worth $2.38M as of Q1 2026.
  • Caption Management sold 284,876 Zevra Therapeutics shares in Q1 2026, an estimated $2.57M.
  • Zevra Therapeutics made up 0.01% of Caption Management's portfolio in Q1 2026, its #777 holding.
  • Caption Management first reported a position in Zevra Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • Caption Management's Zevra Therapeutics position peaked at $4.85M in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.